272 related articles for article (PubMed ID: 31157521)
1. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
2. Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program.
Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
Eur J Haematol; 2022 Nov; 109(5):465-473. PubMed ID: 35811388
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
4. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
5. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
[TBL] [Abstract][Full Text] [Related]
8. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
9. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
Ware RE; Zimmerman SA; Schultz WH
Blood; 1999 Nov; 94(9):3022-6. PubMed ID: 10556185
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea Use Associated with Nonverbal and Executive Skills in Sickle Cell Anemia.
Tarazi RA; Patrick KE; Iampietro M; Apollonsky N
J Pediatr Psychol; 2021 Jul; 46(6):710-718. PubMed ID: 33706380
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.
Jain DL; Apte M; Colah R; Sarathi V; Desai S; Gokhale A; Bhandarwar A; Jain HL; Ghosh K
Indian Pediatr; 2013 Oct; 50(10):929-33. PubMed ID: 23798623
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program.
Nottage KA; Hankins JS; Smeltzer M; Mzayek F; Wang WC; Aygun B; Gurney JG
PLoS One; 2013; 8(8):e72077. PubMed ID: 23967276
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
15. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
16. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E
Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study.
Braga LB; Ferreira AC; Guimarães M; Nazário C; Pacheco P; Miranda A; Picanço I; Seixas T; Rosado L; Amaral JM
Hemoglobin; 2005; 29(3):171-80. PubMed ID: 16114180
[TBL] [Abstract][Full Text] [Related]
18. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
20. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
